| Document |
Document Title |
|
WO2003048375B1 |
Hybrid glycosylated products such as polyketides and peptides are produced by transforming a host cell with (a) a gene cassette for synthesising an activated sugar and (b) nucleic acid encoding a glycosyltransferase (GT). The cell also p...
|
|
WO/2003/061671A1 |
Various macrolide compounds such as those having the following formulas are provided where the variables have the values provided herein.
|
|
WO/2003/062241A1 |
Fused cyclic compounds method of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
|
|
WO/2003/059255A2 |
A process for making water-soluble phosphonooxymethyl ethers of hindered alcohol and phenol containing pharmaceuticals, such as camptothecin, propofol, etoposide, Vitamin E and Cyclosporin A. In particular, the process for preparing wate...
|
|
WO/2003/057707A1 |
The present invention provides a novel ascorbic acid derivative as a provitamin C with improved stability in the body and prolonged life in the body compared to conventionally known 2-O-(&agr -D-glucopyranosyl)ascorbic acid. The composit...
|
|
WO/2003/053988A2 |
A compound of formula (I) wherein the bond marked by formula (II) indicates either the S or the R isomer at the 4''−position&semi and wherein R1 is C1−C12alkyl, C3−C8cycloalkyl&semi or C2−C12alkenyl&semi R2 is, for example, hydro...
|
|
WO/2003/051900A1 |
A compound called NATURA, which is derivative of Isoindigo is useful in aiding the general health of a patient and specifically is beneficial in preventing or treating cancer. This compound and other related Isoindigo, Indigo and Indirub...
|
|
WO/2003/051864A1 |
The invention relates to compounds, formulations, drinks, foodstuffs, methods and therapeutic uses involving, containing, comprising, including and/or for preparing isoflavone conjugate compounds and analogues thereof. More preferably th...
|
|
WO/2003/050132A1 |
6-O-Acyl ketolide antibacterials of formula (I): wherein R?1¿, R?2¿, R?3¿, R?4¿, W, X, X', Y, and Y' are as described herein and in which the substituents have the meaning indicated in the description. These compounds are useful as a...
|
|
WO/2003/047601A1 |
There are described novel 11-O-substituted ketolide derivatives of clarithromycin analogs and pharmaceutically acceptable compositions comprising a therapeutically effective amount of a compound of the invention in combination with a pha...
|
|
WO/2003/047600A1 |
There are described 11-O-substituted macrolides and their descladinose derivatives and pharmaceutically acceptable compositions comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceut...
|
|
WO/2003/048166A1 |
The invention relates to podophyllotoxins, uses thereof and methods of their production.
|
|
WO/2003/046194A1 |
Novel &agr -galactosyl-containing non-reducing disaccharides Gal&agr 1-1βGal and Gal&agr 1-1βGlc expected as useful food materials and medicinal materials which would not damage amino acids or proteins when added to foods or preserved....
|
|
WO/2003/044209A1 |
Using the expression of a molecular chaperone GRP78 as an indication, attempts have been made to search for a substance capable of controlling the expression of GRP78. As a result, versipelostatin (also called JL68) represented by the fo...
|
|
WO/2003/044208A1 |
It is attempted to search for a substance capable of controlling the expression of GRP78, which is one of molecule chaperones, from natural materials using the expression of GRP78 as an indication. As a result, a novel tetronic acid deri...
|
|
WO/2003/043642A1 |
There are described novel substituted tylosin analogs and pharmaceutically acceptable compositions comprinsing a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically acceptable carrier. A...
|
|
WO/2003/042228A1 |
The present invention relates to 14 or 15 membered macrolides substitued at the 4' position of formula (I) and pharmaceutically acceptable salts and solvates thereof, to processes for their preparation and their use in therapy or prophyl...
|
|
WO/2003/040162A1 |
A novel method using novel intermediate products, suitable for advantageous production of desclarithromycin.
|
|
WO/2003/039558A1 |
There are described novel 4' substituted tylosin analogs and pharmaceutically acceptable compositions comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically acceptable carrier....
|
|
WO/2003/040127A1 |
Mono-fluorinated and di-fluorinated benzothiepine apical sodium co-dependent bile acid transport (ASBT) inhibitors are disclosed together with methods of making the same, methods of using the same to treat hyperlipidemic conditions as we...
|
|
WO/2003/035897A2 |
This invention provides new methods for detecting enzyme activity using enzyme substrates comprising an enzyme cleavable portion and a chromogenic portion. The enzyme cleavable portion is a β-D-ribofuranosyl group and the chromogenic po...
|
|
WO/2003/035896A2 |
This invention provides novel chromogenic enzyme substrates which are indoxyl β-D-ribofuranosides. A process for their production is provided. Methods for detecting β-D-ribofuranosidase activity are given. The advantages of these novel...
|
|
WO/2003/035661A1 |
The invention relates to compounds having the following formula (I), in which: R¿a? represents a sugar moiety, an arylamino group, or an alkyl group comprising at least one amino group, R¿b? represents an halogen atom, an halogenoalkyl...
|
|
WO/2003/031430A2 |
The invention relates to flavonoids compounds of formula (I) and (II) capable of modifying the dynamic and/or physical state of biological membranes and to stimulate the endogenous synthesis of stress proteins in eukaryotic cells. Such c...
|
|
WO/2003/029269A1 |
The present invention relates to an improved extraction process for an alkaloid glycoside extract from the species $i(Solanum).
|
|
WO/2003/027049A1 |
A method for extracting a hydrophobic group-containing water-soluble organic compound, comprising the step of bringing an aqueous solution containing the hydrophobic group-containing water-soluble organic compound and a saccharide into c...
|
|
WO/2003/026644A1 |
The present invention provides methods for treating or preventing vascular inflammation or for reducing blood levels of c-reactive protein by administering at least one sterol absorption inhibitor and/or at least one 5-stanol absorption ...
|
|
WO/2003/024984A1 |
Novel polysaccharides comprising one or more oxime linkages are provided. Methods for their preparation include the polycondensation of saccharides bearing oxime-forming substituents. In some embodiments, polymerization is conducted in t...
|
|
WO/2003/024986A1 |
6-O-Carbamate-11,12-lacto-ketolide antimicrobials of the formula (I) wherein R1, R2, R3 R7, and R8 are as described herein and in which the substituents have the meaning indicated in the description. These compounds are useful as antibac...
|
|
WO/2003/020236A2 |
The present invention relates to a natural extract from fungus, cyanobactria, plants, lichens or a mixture thereof having an ultra violet absorbency in the range of 220 nm to 425 nm wherein said extract is obtained by contacting said fun...
|
|
WO/2003/020737A1 |
A compound of formula (I), wherein A is CH¿2? or (CH¿2?)¿2?; R?1¿ is hydrogen, arylalkyl, alkenyl, or alkyl; R?2¿ is alkyl or perfluoroalkyl; and R?3¿ and R?4¿ are as defined herein. Further provided are methods of using such comp...
|
|
WO/2003/017949A2 |
Novel synthetic gangliosides and pharmaceutical compositions containing such synthetic gangliosides are described. Methods of making the novel synthetic ganglioside compounds and compositions as well as their use in the field of neuropro...
|
|
WO/2003/018031A2 |
The present invention relates to a method of treating respiratory infections in humans by administering a single dose of azithromycin.
|
|
WO/2003/014135A1 |
The present invention relates to a novel process for the preparation of acarbose. Said process comprises the steps of: 1) acidifying a fermentation broth containing an acarbose; 2) removing particulates from the fermentation broth; 3) ad...
|
|
WO/2003/014136A1 |
11a−Azalide compounds represented by the following general formula (1) or pharmaceutically acceptable salts thereof: (1) wherein R1 represents hydrogen, C1−10 alkyl, etc.&semi R2represents hydrogen, hydroxy, etc.&semi R3 represents h...
|
|
WO/2003/011879A1 |
$i(In vitro)/cell-free process of preparing a sialylated oligosaccharides are described. The sialylated oligosaccharides include gangliosides. The oligosaccharides linked to various moieties including sphingoids and ceramides. Novel comp...
|
|
WO/2003/011882A1 |
There are described novel 4'-substituted 16-membered macrolides and pharmaceutically acceptable compositions comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically acceptable c...
|
|
WO/2003/011881A2 |
Glucoside and glucuronide derivatives ofhydromorphone, dihydromorphine, and dihydroisomorphine and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising a glucoside or glucuronide derivative ofhydromorphone, d...
|
|
WO/2003/010178A1 |
The invention concerns disaccharides of formula (I) derived from $g(a)-maltosyl fluoride, wherein R?1¿ and R?2¿ are such as defined in Claim 1. Said disaccharides are useful as glycosyl donors in transglycosylation reactions catalysed ...
|
|
WO/2003/010155A1 |
The invention relates to a method for producing novel spinosyn derivatives, which are substituted in the C-21 position by a 1-hydroxy-ethyl radical, to novel spinosyn derivatives of this type per se and to their use for producing novel s...
|
|
WO/2003/010116A2 |
The invention provides compositions and methods for isolating phenolic compounds, particularly isoflavones, from aqueous extracts of plant materials that contain such compounds. The process comprising: (a) providing an aqueous plant extr...
|
|
WO/2003/010240A1 |
A process for modifying the taste and/or odour properties of a food colouring substance having unpleasant taste and/or odour properties is disclosed. Secondly, there is provided a process for obtaining a blue non-bleeding colour that see...
|
|
WO/2003/004059A1 |
Use of an anti-parasitic agent in a sustained release form in the treatment of ectoparasitic infections.
|
|
WO/2003/004509A2 |
Antimicrobial macrolide compounds are provided having formulas II: as well as pharmaceutically acceptable salts, esters or prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections ...
|
|
WO/2003/000674A1 |
It is intended to provide a process for producing a soluble isoflavone−containing composition, which is in a natural state free from any solubilizers or chemical modification, has a high solubility under neutral to acidic conditions an...
|
|
WO/2003/000712A1 |
A nitrogenous heterocyclic derivative represented by the general formula (I), a pharmacologically acceptable salt thereof, or a prodrug of either. These have excellent human SGLT2 inhibitory activity and are useful as a preventive or rem...
|
|
WO/2003/000711A1 |
This invention provides analogs of eleutherobin and the eleuthesides modified at the C-11 position or comprising an epoxide functionality from C-11 to C-12. C-11 to C-12 is an ideal location for conjugating functional moieties to the ele...
|
|
WO/2002/102818A1 |
A process for the preparation of erythromycin compounds by alkylating 2’−O−acetyl−4”−O−formyl−11−oxo−8,9−anh
ydro− erythromycin A 6,9−hemiketal compound (1), characterized by reacting compound (1) with an alkyla...
|
|
WO/2002/102819A1 |
A process for the preparation of 2’−O−acetyl−4”−O−formyl −8,9−anhydroerythromycin A 6,9−hemiketal compound (4), characterized by reacting 2’−O−acetylerythromycin A compound (2) with a fomylating agent to obtain ...
|
|
WO/2002/098893A1 |
A glucopyranosyloxypyrazole derivative represented by the following general formula (I), a pharmaceutically acceptable salt of the derivative, or a prodrug of either. (I) The compound has excellent inhibitory activity against human SGLT1...
|
